← Back to Clinical Trials
Recruiting NCT05621733
A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea
Trial Parameters
Condition Graft-versus-Host Disease
Sponsor Novartis Pharmaceuticals
Study Type OBSERVATIONAL
Phase N/A
Enrollment 127
Sex ALL
Min Age 12 Years
Max Age 100 Years
Start Date 2023-04-07
Completion 2026-05-09
Interventions
ruxolitinib
Brief Summary
This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Jakavi® (ruxolitinib) in the real-world clinical setting in Korean Graft-versus-Host disease (GvHD) patients
Eligibility Criteria
Inclusion Criteria: 1. Patients who diagnosed with GvHD and currently receiving or going to receive Jakavi® treatment according to locally approved label 2. Patients who are willing to provide written informed consent prior to study enrollment Exclusion Criteria: 1. Patients under 12 years old 2. Patients with contraindication according to locally approved label of Jakavi® 3. Patients who receive or are going to receive any investigational medicine during the observation period.
Related Trials
NCT05675930
A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) Aft
View Trial →
NCT07356245
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
View Trial →
NCT00603330
Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (G
View Trial →